Given the long PFS in IGHV unmutated (7-year PFS 58% in the RESONATE-2 trial) (4) and in TP53 altered CLL cases (6-year PFS 61% in a phase II clinical trial) (23) that can already be achieved by continuous BTK inhibition in first-line, these characteristics should no longer be seen as high-risk features for treatment failure per se. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.